These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 22223819)

  • 1. A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia.
    Arnold DM; Heddle NM; Carruthers J; Cook DJ; Crowther MA; Meyer RM; Liu Y; Cook RJ; McLeod A; MacEachern JA; Mangel J; Anderson D; Vickars L; Tinmouth A; Schuh AC; Kelton JG
    Blood; 2012 Feb; 119(6):1356-62. PubMed ID: 22223819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial.
    Ghanima W; Khelif A; Waage A; Michel M; Tjønnfjord GE; Romdhan NB; Kahrs J; Darne B; Holme PA;
    Lancet; 2015 Apr; 385(9978):1653-61. PubMed ID: 25662413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study.
    Godeau B; Porcher R; Fain O; Lefrère F; Fenaux P; Cheze S; Vekhoff A; Chauveheid MP; Stirnemann J; Galicier L; Bourgeois E; Haiat S; Varet B; Leporrier M; Papo T; Khellaf M; Michel M; Bierling P
    Blood; 2008 Aug; 112(4):999-1004. PubMed ID: 18463354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of children with refractory immune thrombocytopenia treated with rituximab.
    Matsubara K; Takahashi Y; Hayakawa A; Tanaka F; Nakadate H; Sakai M; Maeda N; Oka T; Ishii E; Bessho F; Morimoto T; Goto H; Hashii Y; Hatakeyama N; Shirahata A; Imaizumi M
    Int J Hematol; 2014 Apr; 99(4):429-36. PubMed ID: 24609717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).
    Tran H; Brighton T; Grigg A; McRae S; Dixon J; Thurley D; Gandhi MK; Truman M; Marlton P; Catalano J
    Br J Haematol; 2014 Oct; 167(2):243-51. PubMed ID: 25041261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia.
    Zaja F; Volpetti S; Chiozzotto M; Puglisi S; Isola M; Buttignol S; Fanin R
    Am J Hematol; 2012 Sep; 87(9):886-9. PubMed ID: 22718483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple cycles of rituximab therapy in chronic refractory immune thrombocytopenia: a case report with a 10-year follow-up.
    Routy B; Boulassel MR; Spurll GM; Warner MN; Routy JP
    Am J Ther; 2013; 20(2):219-22. PubMed ID: 23466621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab for management of refractory pregnancy-associated immune thrombocytopenic purpura.
    Gall B; Yee A; Berry B; Bircham D; Hayashi A; Dansereau J; Hart J
    J Obstet Gynaecol Can; 2010 Dec; 32(12):1167-1171. PubMed ID: 21176329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura.
    Arnold DM; Dentali F; Crowther MA; Meyer RM; Cook RJ; Sigouin C; Fraser GA; Lim W; Kelton JG
    Ann Intern Med; 2007 Jan; 146(1):25-33. PubMed ID: 17200219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients.
    Khellaf M; Charles-Nelson A; Fain O; Terriou L; Viallard JF; Cheze S; Graveleau J; Slama B; Audia S; Ebbo M; Le Guenno G; Cliquennois M; Salles G; Bonmati C; Teillet F; Galicier L; Hot A; Lambotte O; Lefrère F; Sacko S; Kengue DK; Bierling P; Roudot-Thoraval F; Michel M; Godeau B
    Blood; 2014 Nov; 124(22):3228-36. PubMed ID: 25293768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of children with chronic immune thrombocytopenic purpura and Evans syndrome treated with rituximab.
    Gokcebay DG; Tavil B; Fettah A; Yarali N; Azik FM; Tunc B
    Clin Appl Thromb Hemost; 2013; 19(6):663-7. PubMed ID: 22815318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.
    Stasi R; Pagano A; Stipa E; Amadori S
    Blood; 2001 Aug; 98(4):952-7. PubMed ID: 11493438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
    Koulova L; Alexandrescu D; Dutcher JP; O'Boyle KP; Eapen S; Wiernik PH
    Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Persistent hypogammaglobulinemia in an ITP patient following treatment with rituximab].
    Toubi E
    Harefuah; 2012 Nov; 151(11):620-1, 655. PubMed ID: 23367731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes of patients treated with rituximab as second-line treatment for adult immune thrombocytopenia - Follow-up of the RITP study.
    Tjønnfjord E; Holme PA; Darne B; Khelif A; Waage A; Michel M; Ben Romdhan N; Ghanima W
    Br J Haematol; 2020 Nov; 191(3):460-465. PubMed ID: 32342497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab for children with immune thrombocytopenia: a systematic review.
    Liang Y; Zhang L; Gao J; Hu D; Ai Y
    PLoS One; 2012; 7(5):e36698. PubMed ID: 22666325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia.
    Zaja F; Baccarani M; Mazza P; Bocchia M; Gugliotta L; Zaccaria A; Vianelli N; Defina M; Tieghi A; Amadori S; Campagna S; Ferrara F; Angelucci E; Usala E; Cantoni S; Visani G; Fornaro A; Rizzi R; De Stefano V; Casulli F; Battista ML; Isola M; Soldano F; Gamba E; Fanin R
    Blood; 2010 Apr; 115(14):2755-62. PubMed ID: 20130241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France.
    Moulis G; Lapeyre-Mestre M; Mahévas M; Montastruc JL; Sailler L
    Am J Hematol; 2015 Apr; 90(4):301-5. PubMed ID: 25557586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenia refractory to conventional therapy.
    Miyakawa Y; Katsutani S; Yano T; Nomura S; Nishiwaki K; Tomiyama Y; Higashihara M; Shirasugi Y; Nishikawa M; Ozaki K; Abe T; Kikuchi K; Kanakura Y; Fujimura K; Ikeda Y; Okamoto S
    Int J Hematol; 2015 Dec; 102(6):654-61. PubMed ID: 26466831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
    Chouhan JD; Herrington JD
    Pharmacotherapy; 2010 Jul; 30(7):666-83. PubMed ID: 20575632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.